|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Gross profit | |||
| Research and development expenses | |||
| Selling and marketing expenses | |||
| General and administrative expenses | |||
| Other expenses | |||
| Other expenses (income) | |||
| Operating Loss | |||
| Finance expenses | |||
| Finance income | |||
| Loss before income tax | |||
| Income tax expenses | |||
| Net Loss | |||
| Amounts that shall not be subsequently reclassified to profit and loss: | |||
| Gain (loss) from remeasurement of defined benefit plans | |||
| Total comprehensive Loss attributed to the shareholders of the Company | |||
| Basic loss per share (in $) (in Dollars per share) | |||
| Weighted average of the number of ordinary shares used to calculate basic earnings per share (in Shares) | |||
| Diluted loss per share (in $) (in Dollars per share) | |||
| Weighted average of the number of ordinary shares used to calculate diluted earnings per share (in Shares) |
Loading...
